Please assess the completion status of the following clinical trial:

Trial Title: Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participants of either gender aged ≥ 50 years~* Diagnosis of Non-foveal GA secondary to dry AMD~Exclusion Criteria:~* Evidence of Choroidal Neovascularization (CNV)~* GA secondary to any condition other than AMD~* Any prior treatment for AMD or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals~* Any intraocular surgery or thermal laser within three (3) months of trial entry~* Any prior thermal laser in the macular region, regardless of indication~* Any ocular or periocular infection in the twelve (12) weeks~* Previous therapeutic radiation in the region of the study eye~* Any sign of diabetic retinopathy in either eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zimura 1 mg [Part 1] (Type: EXPERIMENTAL): Participants received 1 mg of Zimura in the study eye administered via IVT injection (50 µL) on Day 1 and monthly up to 18 months.
- Zimura 2 mg [Part 1] (Type: EXPERIMENTAL): Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) on Day 1 and monthly up to 18 months.
- Sham [Part 1] (Type: SHAM_COMPARATOR): Participants received a Sham injection of an empty, needleless syringe administered in the study eye on Day 1 and monthly up to 18 months.
- Zimura 2 mg (Zimura 2mg+Sham) [Part 2] (Type: EXPERIMENTAL): Participants received 2 mg of Zimura in the study eye administered via IVT injection (100 µL) and a subsequent Sham administration on Day 1 and monthly up to 18 months.
- Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] (Type: EXPERIMENTAL): Participants received 4 mg of Zimura in the study eye administered via two consecutive IVT injections (2 x 100 µL) on Day 1 and monthly up to 18 months.
- Sham (Sham+Sham) [Part 2] (Type: SHAM_COMPARATOR): Participants received two consecutive Sham injections of empty, needleless syringes administered in the study eye on Day 1 and monthly up to 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).